FDA Rejects Diet Pill Qnexa from Diet Pharmaceutical Drugs List in Panel Vote
Get instant savings up to 75%
Download the Free PrescriptionDrugs.com Discount Drug Card
Print Card
Redeem for instant savings up to 75% on name brand
& generic prescription drugs
Accepted at over 60,000 pharmacies nationwide
Qnexa, the first of three diet pills on the pharmaceutical drugs list awaiting approval from the FDA, has been rejected. The fate of two other diet drugs, Contrave and a third revolutionary drug produced by Arena Pharmaceuticals, which regulates serotonin levels in the brain, is still unknown. They remain on the Rx drug list awaiting review and are scheduled to be reviewed in September and December respectively.
About Qnexa
Qnexa combines phentermine and topiramate to reduce appetite and leave the patient feeling satiated. This drug combination is not new and other diet Rx drug list contain the same medications in lower doses.
The panel reviewed if Qnexa’s risk and benefit assessment produced an overall benefit to obese patients; however after discussion of its health risks, FDA panellists voted 6 to 10 against the drug, concerned about its side effects, botching Qnexa from the pharmaceutical drugs list to treat obesity.
The drug did meet the FDA’s criteria in producing significant weight loss in patients. For a diet drug to be approved, it must produce at least a 5% weight loss in one year. However, the panel maintained reservations about long term side effects, such as birth defects, depression, and heart irregularities.
Learning More about Prescription Drugs
As obesity becomes an increasing concern, the pharmaceutical industry has been trying to add other obesity fighting drugs to the pharmaceutical drugs list to its short list of medication treatment options.
To learn more about the medications referred to in this article, PrescriptionDrugs.com encourages consumers to browse the prescription drugs list, which contains all manner of information regarding the most popular drugs on the market today.
